Business - n.a.

Intercell: Vaccine Development to Suspend

Published: April 11, 2011; 12:19 · (Vindobona)

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

Intercell: Vaccine Development to Suspend / Picture: © Intercell

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.

Although…

This article includes a total of 139 words.

or Log In

Fast News Search

Join us to succeed in Vienna! Sign up to read articles for free and to get personalized updates on the events that interest you.

Intercell: Vaccine Development to Suspend

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

Join us to succeed in Vienna!
Sign up to read articles for free and to get personalized updates on the events that interest you.